Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 58.32 as of 2026-10-06T12:06:01.614Z.
Consensus retrieved: 2026-10-06T10:00:53.530Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:06:01.614Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 910caa8056250a98c6dba3c9bb66883dbb084468cd81c957cd22bc1e41af4ee2
Forward PE Ratio (58.32) = Dated Quote Price ($69.85) / Consensus Forward EPS ($1.20)
FORWARD PE RATIO
58.32
SECTOR MEDIAN · HEALTHCARE
19.84
median of 122 covered companies
CURRENT VS SECTOR MEDIAN
+194.03%
vs the sector median at left
CareDx, Inc
Market Cap
$3.61B
Forward PE Ratio
58.32
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CareDx, Inc (CDNA) | $3.61B | 58.32 |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 32.65 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 50.59 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | N/A |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A |
Trailing P/E
33.7
reported TTM EPS
Forward P/E
58.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.20 implies -42.0% EPS decline vs the reported trailing $2.07.
At the dated quote price of $69.85, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.20 | $1.18 – $1.22 | 4 | 58.3x |
| 2027-12-31 | $1.29 | $1.27 – $1.31 | 4 | 54.2x |
| 2028-12-31 | $1.84 | $1.28 – $2.72 | 3 | 38.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
